Table 4 Multivariate analysis of survival in patients with stages II and III BTC
Prognostic factor | Hazard ratio | 95% CI | P value |
|---|---|---|---|
Overall survival | |||
Lymph node (negative vs. positive) | 0.461 | 0.208–1.021 | 0.056 |
Serum CA 19-9 level (<37 vs. ≥37 U/mL) | 0.379 | 0.177–0.811 | 0.012 |
Treatment (adjuvant chemotherapy vs. observation) | 0.231 | 0.087–0.617 | 0.003 |
Recurrence-free survival | |||
Lymph node (negative vs. positive) | 0.579 | 0.269–1.250 | 0.164 |
Serum CA 19-9 level (<37 vs. ≥37 U/mL) | 0.392 | 0.189–0.811 | 0.012 |
Treatment (adjuvant chemotherapy vs. observation) | 0.385 | 0.161–0.923 | 0.032 |